Spyros uses microscope

What is mesothelioma?

Mesothelioma is a cancer that most commonly affects the linings of the lung (pleural mesothelioma), and in rarer cases the linings of the abdomen (peritoneal mesothelioma). It is caused in the great majority of cases by past asbestos exposure. The cancer is aggressive, often producing great pain in the chest wall. It responds poorly to all therapies, including surgery, and the average survival from diagnosis is less than a year.

Read more about this disease.

Read Prof Tony Newman Taylor's blog post about the history of asbestos.

Information for patients

The scale of the problem

The UK has the highest incidence of mesothelioma in the world. This aggressive form of cancer results in 2,500 deaths a year in the UK, and it is estimated that there will be 50,000 to 60,000 new cases by 2050. Mesothelioma is so prevalent in the UK in part due to the use of asbestos not being reduced earlier and our legacy of a large shipbuilding industry. In many cases spouses and children of those exposed to asbestos have developed the cancer through transfer of fibres on workers’ clothing. Asbestos exposure has put servicemen and women in the armed forces at particular risk.  Asbestos exposure has an equally high risk of causing lung cancer, leading to a further 2,500 deaths each year. Lung cancer itself is the major cause of cancer death in the UK.

Why there is cause for optimism

Cancer research is famed for breakthroughs, and many formerly incurable cancers are now treatable. This revolution has arisen because the Human Genome Project has made it possible to find the corrupted (mutated) genes that drive cancer growth, and to study systematically how they alter the growth and spread of cancer cells.  

Redressing the balance

In contrast to other cancers, such as those of the breast and prostate, efforts to understand the mutations that drive mesothelioma and lung cancer have until recently been neglected and remain at an early stage. The National Centre for Mesothelioma Research (NCMR) based in the National Heart and Lung Institute (NHLI) of Imperial College aims to lead discovery research aimed at the underlying mechanisms of mesothelioma and lung cancer, identifying new targets for therapy and new diagnostics for patient stratification.

Background and further detail on the Centre

NCMR Deputy Director Prof Miriam Moffatt talks about mesothelioma, its causes and its occurrence in the UK.

What is mesothelioma?

NCMR Deputy Director Prof Miriam Moffatt talks about mesothelioma, the causes of the disease and its occurrence in the UK.

mesothelioma network

Why a Centre?

The Centre represents a collaborative structure based at the National Heart and Lung Institute (NHLI, Imperial College London), The Royal Brompton and Royal Marsden NHS Trusts (RBHT and RMHT), and the Institute for Cancer Research (ICR).

By creating a designated research unit within NHLI and Imperial College we can focus on targetted research that works towards better treatment, but the Centre extends beyond these institutions to include national and international collaborators. Read more about our collaborators here.

The Centre will be integrated with and draw from existing clinical and patient networks in the UK, with patient and family involvement central to all aspects of the Centre.